Body Mass Index and C-reactive Protein Are Potential Predictors of Asthma Development in Egyptian Polycystic Ovary Syndrome Patients

Overview

Journal J Med Biochem

Specialty Biochemistry

Date 2019 Sep 10

PMID 31496906

Citations 8

Authors

Hebatallah Ahmed Nasser

Nermeen Zakaria Abuel Ezz

Heidi Mohamed Abdel-Mageed

Rasha Ali Radwan

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies suggest asthma prevalence in polycystic ovary syndrome (PCOS) patients. This is the first study to explore asthma prevalence among Egyptian PCOS patients. It highlighted common findings in PCOS and asthma. It investigated whether these findings could serve as potential predictors of asthma.

Methods: A hundred PCOS patients, sixty asthmatic patients and thirty apparently healthy females of matched age were included. Body mass index (BMI), C-reactive protein (CRP), IL-6, IgE, 25 (OH) vitamin D, testosterone and lipid profile were measured.

Results: Both PCOS and asthmatics had significantly higher BMI, Total cholesterol (TC), LDL-C, IgE, CRP and IL-6 (P<0.001) and lower 25 (OH) vitamin D levels (P<0.001) compared to controls. Within the PCOS group, 47 patients developed asthma with a significant increase in BMI (P=0.003), CRP and IgE levels (P<0.001) compared to non-asthmatic PCOS. Both asthmatic PCOS and asthmatics expressed elevated BMI, IgE, IL-6 and CRP levels, but with no significant difference between them. Asthmatic PCOS showed significantly higher testosterone and dyslipidemia profile. Multivariate regression revealed that BMI and CRP could predict asthma development within PCOS (OR=1.104, C.I 1.004-1.2 and OR=1, C.I. 1-1.02), respectively. Receiver operating characteristic (ROC) curve showed that BMI and CRP at a cutoff value 28.5 kg/m and 117.6 nmol/L respectively could differentiate between asthmatic and non-asthmatic PCOS with sensitivity 63.8 % and specificity 62% for BMI, and sensitivity and specificity of 66% for CRP.

Conclusions: This study shows that BMI and CRP are predictors of asthma development in Egyptian PCOS.

Citing Articles

The Effect of BMI and Lipid Metabolism on Pregnancy Outcomes of PCOS Patients Treated with ICSI_IVF.

Ghamari M, Akbari Asbagh F, Riahi M J Obstet Gynaecol India. 2024; 74(2):144-149.

PMID: 38707877 PMC: 11065796. DOI: 10.1007/s13224-023-01879-0.

Effect of Consultation Number on the Assessment and Treatment of Polycystic Ovary Syndrome.

Wang Y, Chen J, Dong H, Ma R, Zou Y, Wang W Int J Womens Health. 2024; 16:527-541.

PMID: 38558831 PMC: 10979685. DOI: 10.2147/IJWH.S445568.

Potentials of curcumin against polycystic ovary syndrome: Pharmacological insights and therapeutic promises.

Akter T, Zahan M, Nawal N, Rahman M, Tanjum T, Arafat K Heliyon. 2023; 9(6):e16957.

PMID: 37346347 PMC: 10279838. DOI: 10.1016/j.heliyon.2023.e16957.

Relation Between Non-Alcoholic Fatty Pancreas and Clinical and Biochemical Parameters in Women with Polycystic Ovary Syndrome: A Multi-Centric Study.

Osman M, Alkhouly M, Elmohaseb G, Nassef E, Mohamed I, El Mancy I Int J Gen Med. 2022; 15:8225-8233.

PMID: 36438020 PMC: 9682932. DOI: 10.2147/IJGM.S384073.

Combined score of C-reactive protein level and neutrophil-to-lymphocyte ratio: A novel marker in distinguishing children with exacerbated asthma.

Zhu X, Zhou L, Li Q, Pan R, Zhang J, Cui Y Int J Immunopathol Pharmacol. 2021; 35:20587384211040641.

PMID: 34514899 PMC: 8442497. DOI: 10.1177/20587384211040641.

References

Daan N, Koster M, de Wilde M, Dalmeijer G, Evelein A, Fauser B . Biomarker Profiles in Women with PCOS and PCOS Offspring; A Pilot Study. PLoS One. 2016; 11(11):e0165033. PMC: 5091782. DOI: 10.1371/journal.pone.0165033. View

Fukuyama N, Homma K, Wakana N, Kudo K, Suyama A, Ohazama H . Validation of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol. J Clin Biochem Nutr. 2008; 43(1):1-5. PMC: 2459246. DOI: 10.3164/jcbn.2008036. View

Beasley R, Semprini A, Mitchell E . Risk factors for asthma: is prevention possible?. Lancet. 2015; 386(9998):1075-85. DOI: 10.1016/S0140-6736(15)00156-7. View

Khan U, Rastogi D, Isasi C, Coupey S . Independent and synergistic associations of asthma and obesity with systemic inflammation in adolescents. J Asthma. 2012; 49(10):1044-50. DOI: 10.3109/02770903.2012.728271. View

Zierau L, Gade E, Lindenberg S, Backer V, Thomsen S . Coexistence of asthma and polycystic ovary syndrome: A concise review. Respir Med. 2016; 119:155-159. DOI: 10.1016/j.rmed.2016.08.025. View

Bakeer E, Radwan R, El Mandoury A, El Rahman A, Gad M, El Maksoud S . Anti-Müllerian Hormone as a Diagnostic Marker in Egyptian Infertile Polycystic Ovary Syndrome Females: Correlations with Vitamin D, Total Testosterone, Dyslipidemia and Anthropometric Parameters. J Med Biochem. 2018; 37(4):448-455. PMC: 6298483. DOI: 10.1515/jomb-2017-0068. View

Kim J, Choi Y . Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013; 56(3):137-42. PMC: 3784112. DOI: 10.5468/ogs.2013.56.3.137. View

Poynter M, Irvin C . Interleukin-6 as a biomarker for asthma: hype or is there something else?. Eur Respir J. 2016; 48(4):979-981. PMC: 5518110. DOI: 10.1183/13993003.01597-2016. View

Perkins N, Schisterman E . The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006; 163(7):670-5. PMC: 1444894. DOI: 10.1093/aje/kwj063. View

10.

Kudo M, Ishigatsubo Y, Aoki I . Pathology of asthma. Front Microbiol. 2013; 4:263. PMC: 3768124. DOI: 10.3389/fmicb.2013.00263. View

11.

Weiss S . Obesity: insight into the origins of asthma. Nat Immunol. 2005; 6(6):537-9. DOI: 10.1038/ni0605-537. View

12.

Blagojevic I, Ignjatovic S, Macut D, Kotur-Stevuljevic J, Bozic-Antic I, Vekic J . Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (the Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity. J Med Biochem. 2018; 37(4):476-485. PMC: 6298479. DOI: 10.2478/jomb-2018-0008. View

13.

Haldar P, Pavord I, Shaw D, Berry M, Thomas M, Brightling C . Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008; 178(3):218-224. PMC: 3992366. DOI: 10.1164/rccm.200711-1754OC. View

14.

Bentley-Lewis R, Seely E, Dunaif A . Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2011; 40(2):433-49, ix-x. PMC: 3253555. DOI: 10.1016/j.ecl.2011.01.009. View

15.

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

16.

Diamanti-Kandarakis E, Papavassiliou A, Kandarakis S, Chrousos G . Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007; 18(7):280-5. DOI: 10.1016/j.tem.2007.07.004. View

17.

Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber T . Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009; 161(4):575-82. DOI: 10.1530/EJE-09-0432. View

18.

Avci E, Alp Avci G . Important Biomarkers that Play a Role in the Chronic Obstructive Pulmonary Disease Process. J Med Biochem. 2018; 37(1):46-53. PMC: 6294106. DOI: 10.1515/jomb-2017-0035. View

19.

Diamanti-Kandarakis E, Dunaif A . Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33(6):981-1030. PMC: 5393155. DOI: 10.1210/er.2011-1034. View

20.

Escobar-Morreale H, Luque-Ramirez M, Gonzalez F . Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2010; 95(3):1048-58.e1-2. PMC: 3079565. DOI: 10.1016/j.fertnstert.2010.11.036. View